The intrarenal renin-angiotensin system: Does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice

Nephrology Dialysis Transplantation

Volumn 28, Issue 12, 2013, Pages 2977-2982

  Lu, Xifeng ^a   Roksnoer, Lodi C W ^a   Danser, Alexander H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibitor; Angiotensin; Chymase; Diabetes; Hypertension; Renin

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; NITRIC OXIDE SYNTHASE INHIBITOR; PRORENIN;

ANGIOTENSIN BLOOD LEVEL; BLOOD PRESSURE; DIABETES MELLITUS; ENZYME ACTIVE SITE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RETINOPATHY; REVIEW; SODIUM TRANSPORT; UPREGULATION;

ACE INHIBITOR; ANGIOTENSIN; CHYMASE; DIABETES; HYPERTENSION; RENIN;

ANGIOTENSIN II; ANIMALS; HYPERTENSION; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890022318     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft333     Document Type: Review

References (33)

1. Van Kats JP, Schalekamp MADH, Verdouw PD et al. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60: 2311-2317
2. Van Kats JP, de Lannoy LM, Danser AHJ et al. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 1997; 30: 42-49
3. Van Kats JP, van Meegen JR, Verdouw PD et al. Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens 2001; 19: 583-589
4. Van Esch JHM, Gembardt F, Sterner-Kock A et al. Cardiac phenotype and angiotensin II levels in AT1a, AT1b and AT2 receptor single, double and triple knockouts. . Cardiovasc Res 2010; 86: 401-409
5. Batenburg WW, Krop M, Garrelds IM et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25: 2441-2453
6. Batenburg WW, Lu X, Leijten F et al. Renin-and prorenininduced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? Hypertension 2011; 58: 1111-1119
7. Price DA, Porter LE, Gordon M et al. The paradox of the lowrenin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-2391
8. Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H et al. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension 2004; 44: 223-229
9. Kang JJ, Toma I, Sipos A et al. The collecting duct is the major source of prorenin in diabetes. Hypertension 2008; 51: 1597-1604
10. Luetscher JA, Kraemer FB, Wilson DM et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417
11. Deinum J, Ronn B, Mathiesen E et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulindependent diabetes mellitus. Diabetologia 1999; 42: 1006-1010
12. Danser AHJ, van den Dorpel MA, Deinum J et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989; 68: 160-167
13. Van den Heuvel M, Batenburg WW, Jainandunsing S et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin- aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens 2011; 29: 2147-2155
14. De Lannoy LM, Danser AHJ, van Kats JP et al. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997; 29: 1240-1251
15. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002; 61: 579-585
16. Kobori H, Prieto-Carrasquero MC, Ozawa Y et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004; 43: 1126-1132
17. Gonzalez-Villalobos RA, Satou R, Seth DM et al. Angiotensinconverting enzyme-derived angiotensin II formation during angiotensin II-induced hypertension. Hypertension 2009; 53: 351-355
18. Metzger R, Bohle RM, Pauls K et al. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int 1999; 56: 1442-1454
19. Alexiou T, Boon WM, Denton DA et al. Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice. J Hypertens 2005; 23: 945-954
20. Tanimoto K, Sugiyama F, Goto Y et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994; 269: 31334-31337.
21. Hilgers KF, Reddi V, Krege JH et al. Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme. Hypertension 1997; 29: 216-221
22. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest 2013; 123: 2011-2023
23. Herrera M, Sparks MA, Alfonso-Pecchio AR et al. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension 2013; 61: 253-258
24. Ong FS, Lin CX, Campbell DJ et al. Increased angiotensin IIinduced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity. Hypertension 2012; 59: 283-290
25. Fisher NDL, Danser AHJ, Nussberger J et al. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117: 3199-3205
26. Schuijt MP, van Kats JP, de Zeeuw S et al. Cardiac interstitial fluid levels of angiotensin I and II in the pig. J Hypertens 1999; 17: 1885-1891
27. Cassis LA, Huang J, Gong MC et al. Role of metabolism and receptor responsiveness in the attenuated responses to angiotensin II in mice compared to rats. Regul Pept 2004; 117: 107-116
28. Matsusaka T, Niimura F, Shimizu A et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol 2012; 23: 1181-1189
29. Van Esch JH, Tom B, Dive V et al. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 2005; 45: 120-125
30. Fuchs S, Xiao HD, Hubert C et al. Angiotensinconverting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008; 51: 267-274
31. Tom B, de Vries R, Saxena PR et al. Bradykinin potentiation by angiotensin-(1-7) and angiotensin-converting enzyme (ACE) inhibitors correlates with ACE C-and N-domain blockade. Hypertension 2001; 38: 95-99
32. Danser AHJ. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol 2007; 50: 105-111
33. Klotz S, Burkhoff D, Garrelds IM et al. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur Heart J 2009; 30: 805-812